Wells Fargo’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Wells Fargo’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-17,024	Closed	-$45K	–	7229
2020 Q1	$45K	Buy	17,024 +379	+2%	+$621	﹤0.01%	5381
2019 Q4	$19K	Buy	16,645 +11	+0.1%	+$18	﹤0.01%	5762
2019 Q3	$29K	Buy	16,634 +561	+3%	+$1.71K	﹤0.01%	5718
2019 Q2	$76K	Sell	16,073 -170	-1%	-$952	﹤0.01%	5413
2019 Q1	$104K	Sell	16,243 -5	-0%	-$26	﹤0.01%	5118
2018 Q4	$82K	Buy	16,248 +14,156	+677%	+$99.1K	﹤0.01%	5375
2018 Q3	$18K	Buy	2,092 +1,092	+109%	+$12.1K	﹤0.01%	5856
2018 Q2	$13K	Buy	+1,000	New	+$13.7K	﹤0.01%	5913

Wells Fargo's NTGN Position: Q2 2020 in Review

Wells Fargo sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 17,024 shares — an estimated $45K sold.

Wells Fargo first reported a position in NTGN in Q2 2018 and held it in 8 quarters. The position peaked at $104K in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Wells Fargo reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Wells Fargo sold 17,024 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $45K.
Wells Fargo first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Wells Fargo's Neon Therapeutics, Inc. Common Stock position peaked at $104K in Q1 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Wells Fargo's 13F filing for Q2 2020, filed 13 Aug 2020.